Cabergolina review

Cabergolina is a combination of derived ergot fungi alkaloids used to treat Parkinson’s disease, and some hormone problems such as excessive prolactin production. This medication is used to prevent and inhibit progressive breast milk production in lactating mothers, but is not as effective when the patient has recently given birth. Additionally, this medication can be used to impede functional output of prolactin producing or causing tumors and as a hormone regulator for certain types of ovarian diseases.

In a cellular level, this medication inhibits dopamine receptors in the hypothalamus, more specifically in the lactophilic cells, which in turn inhibits the reception of signals in the pituitary gland to release prolactin. Cabergolina is considered an effective alternative to Bromocriptine if the latter is ineffective in treating prolactin production disorders.

Patients with early onset symptoms of Parkinson's disease may benefit from single medication type therapy with Cabergolina. It may also be used in conjunction with certain medications such as levodopa or carbidopa to treat much later stages of Parkinson's.

This medication is also advised and prescribed by physicians as treatment for microprolactinomas or malfunction of the prolactin producing tumors in the pituitary gland. This is highly evident with those patients having hyperactive pituitary glands.

As an alternative for Bromocriptine, it may also be used as treatment of amenorrhea, anovulation, and galactorrhea.

In some cases, Cabergolina has been used to heighten and correct issues pertaining to libido dysfunction and anorgasmia. Bodybuilders have taken advantage of the medication's effects as a means to combat the occurrence of gynecomastia, which is a rather common side effect of anabolic steroid medications.

As a monotherapeutic medication for Parkinson's disease, the recommended dosage is an initial dose of .5 milligram daily, and increased to a dose of 2 to 4 milligram per day. As a combinant medication to levodopa or carbidopa, it could be adjusted to a maximum of 2 to 6 milligram doses per day.

For cancerous cells and tumors, or perhaps hyperprolactinemic disorders, an initial 0.5 milligram dose per week may be used and administered, with a gradual increase to 4.5 milligram per week, as necessary and as prescribed by the physician. Doctors may modify the actual recommended dosage depending on the patient’s response to the treatment and their condition.

The most common side effect is weakness, followed by fatigue or body malaise. In more severe cases, vomiting is evident, with combined headache and dizziness. It is advisable to notify your doctor of any unusual symptoms after taking the medication.

There are also cases wherein hypertension develops. Due to the effect of prolactin inhibition, pain in the breast area may be felt as an indirect effect to target tissue.

For pregnant or lactating mothers, it is highly discouraged to prescribe this medication unless gravely necessary as it disrupts the normal development of the child with hormonal curbing. Furthermore, the medication is known to pass through milk during breastfeeding and may pose a serious threat to the nursing baby.

Cabergolina has the following structural formula:

Chemical structure of cabergolina

• Molecular formula of cabergolina is C26H37N5O2
Cabergolina available : 0,5mg tablets

Generic name: Cabergoline

Brand name(s): Cabaser, Cabergolinum, Dostinex

  Your Cabergolina review